Having trouble accessing articles? Reset your cache.

Changing of the guard at NICE

When Andrew Dillon steps down as NICE's chief executive in March 2020, his successor will be tasked with leading an agency that faces an increasingly complex and fast-moving medicines landscape.

The U.K. agency is already going through a period of change after 20 years under Dillon's

Read the full 468 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers